Cencora, Inc. $COR Position Lowered by Aurora Investment Counsel

Aurora Investment Counsel reduced its position in Cencora, Inc. (NYSE:COR) by 10.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,635 shares of the company’s stock after selling 632 shares during the quarter. Aurora Investment Counsel’s holdings in Cencora were worth $1,690,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of COR. Atlantic Edge Private Wealth Management LLC increased its holdings in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares during the last quarter. Cornerstone Planning Group LLC boosted its holdings in Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock worth $26,000 after purchasing an additional 48 shares during the period. Costello Asset Management INC bought a new stake in Cencora during the first quarter valued at $28,000. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Cencora during the first quarter worth $39,000. Finally, Golden State Wealth Management LLC raised its holdings in shares of Cencora by 157.6% during the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company’s stock worth $47,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the transaction, the chief executive officer owned 39,274 shares of the company’s stock, valued at $11,389,460. The trade was a 11.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on COR shares. Mizuho boosted their price objective on shares of Cencora from $316.00 to $334.00 and gave the company an “outperform” rating in a research report on Thursday. Wells Fargo & Company upped their target price on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Jefferies Financial Group raised their price target on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, June 30th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, Evercore ISI set a $340.00 price objective on Cencora in a research note on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $324.91.

Cencora Trading Up 0.9%

Cencora stock opened at $327.56 on Tuesday. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $329.58. The stock has a market capitalization of $63.51 billion, a PE ratio of 33.70, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The firm has a 50 day simple moving average of $301.04 and a 200-day simple moving average of $293.60. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53.

Cencora (NYSE:COR) last released its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. During the same period in the prior year, the firm posted $3.34 earnings per share. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora’s payout ratio is presently 22.63%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.